A letter from Roche
The enrolment in the Phase III trial GENERATION HD1 study has been increased from 660 to 801 participants worldwide, as well as being extended to China.
This change does not impact participants already enrolled in the study, but it allows for additional patients to enrol in the three existing study groups.
By enrolling more participants, Roche and Genentech will receive more data and increase the statistical power of the study! Read the full letter from Roche!